Last reviewed · How we verify

IVF: Decapeptyl and hCG — Competitive Intelligence Brief

IVF: Decapeptyl and hCG (IVF: Decapeptyl and hCG) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist + gonadotropin. Area: Reproductive Medicine / Fertility.

phase 3 GnRH agonist + gonadotropin GnRH receptor (Decapeptyl); LH/hCG receptor (hCG) Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

IVF: Decapeptyl and hCG (IVF: Decapeptyl and hCG) — The University of Hong Kong. Decapeptyl (triptorelin) suppresses gonadotropin-releasing hormone (GnRH) to downregulate the pituitary-gonadal axis, while hCG (human chorionic gonadotropin) triggers final oocyte maturation and ovulation in assisted reproductive technology.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IVF: Decapeptyl and hCG TARGET IVF: Decapeptyl and hCG The University of Hong Kong phase 3 GnRH agonist + gonadotropin GnRH receptor (Decapeptyl); LH/hCG receptor (hCG)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GnRH agonist + gonadotropin class)

  1. The University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IVF: Decapeptyl and hCG — Competitive Intelligence Brief. https://druglandscape.com/ci/ivf-decapeptyl-and-hcg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: